Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia

Kaplan, Steven A.; Holtgrewe, H. Logan; Bruskewitz, Reginald C.; Saltzman, Brian; Mobley, David F.; Narayan, Perinchery; Lund, Robert H.; Weiner, Saul J.; Wells, G.R.; Cook, Thomas J.; Meehan, Alan G.; Waldstreicher, Joanne

doi:10.1016/s0090-4295(01)00985-2

Cited by 40 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Age was not a factor in the efficacy of finasteride 37. There was no impact on bone mineral density in men treated with finasteride 38. The Finasteride Urodynamics Study Group evaluated pressure-flow parameters in men receiving finasteride for 2 years and found that men with prostate volumes greater than 40 mL continued to have decreases in detrusor pressure at Qmax throughout the course of the study 39…”

Section: -Alpha-reductase Inhibitorsmentioning

confidence: 99%

Therapeutic options in the treatment of benign prostatic hyperplasia

Sandhu¹

2009

PPA

View full text Add to dashboard Cite

Current theraputic options for the treatment of symptomatic benign prostatic hyperplasia (BPH) are reviewed. Therapeutic options for mild lower urinary tract symptoms (LUTS), as defined by the American Urological Association, are generally treated medically. Moderate to severe LUTS can be treated medically or with surgical therapy. Current medical and surgical treatments for LUTS secondary to BPH are reviewed and evolving treatments are explored.

show abstract

Section: -Alpha-reductase Inhibitorsmentioning

confidence: 99%

Therapeutic options in the treatment of benign prostatic hyperplasia

Sandhu¹

2009

PPA

View full text Add to dashboard Cite

show abstract

“…What are these parameters? It has been shown in many publications that the response to a-blockers and 5-ARIs is similarly independent of the patient's age and even symptom severity at the beginning of treatment, 26,27 although the adverse events reported with different a-blockers may vary with age. 28,29 Breaking down the LUTS into irritative/ storage vs obstructive/voiding symptoms may help to some degree in distinguishing responses to 5-ARIs but not necessarily to a-blockers, which reduce all symptoms to an equal degree.…”

Section: Serum Psa and Response To Medical Therapymentioning

confidence: 99%

The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia

Roehrborn

2008

Int J Impot Res

View full text Add to dashboard Cite

Several analyses have demonstrated a clinically useful relationship between serum prostate specific antigen (PSA) and prostate volume in men with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Both prostate volume and serum PSA predict certain aspects of the natural history of LUTS and BPH, and men with higher PSA and larger glands in general have a higher rate of progression measured by various parameters. Serum PSA also predicts the response to certain types of medical therapy in men with LUTS and BPH and is thus useful in the evaluation and management of these patients. Lastly, serum PSA does not loose its usefulness as a cancer marker for prostate cancer even if certain medications reduce serum PSA values predictably by 50%.

show abstract

“…Patients with baseline serum PSA levels higher than 1.4 ng/mL and enlarged prostates had the best response to finasteride versus placebo. Age was not a factor in the efficacy of finasteride [21]. There was no impact on bone mineral density in men treated with finasteride [22].…”

Section: -α-Reductase Overviewmentioning

confidence: 82%

The role of 5-α-reductase inhibition as monotherapy in view of the MTOPS data

Sandhu

2004

Curr prostate rep

View full text Add to dashboard Cite

Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia

Cited by 40 publications

References 15 publications

Therapeutic options in the treatment of benign prostatic hyperplasia

Therapeutic options in the treatment of benign prostatic hyperplasia

The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia

The role of 5-α-reductase inhibition as monotherapy in view of the MTOPS data

Contact Info

Product

Resources

About